Healwell AI Inc. is navigating a critical juncture. The company, which recently completed a landmark fiscal year, is now preparing to report its first-quarter 2026 results, a period management has already flagged as likely the weakest of the year. This upcoming report, expected on May 19, 2026, will serve as the first real test of whether last year’s dramatic financial turnaround is sustainable.
Fiscal 2025 was a transformative period for the healthcare AI firm. Revenue from continuing operations skyrocketed by 427 percent to approximately 103.8 million Canadian dollars, up from just under 20 million CAD the prior year. More significantly, Healwell achieved its first full year of positive adjusted EBITDA, posting 2.3 million CAD. The fourth quarter alone saw adjusted EBITDA swing from negative 5 million CAD to positive 1.4 million CAD, marking the third consecutive profitable quarter on that metric. Despite these operational gains, the company’s stock currently trades about 52 percent below its 52-week high, reflecting persistent market skepticism toward high-growth technology stocks that remain unprofitable on a net basis. For the full year, Healwell reported an IFRS net loss of 39.1 million CAD.
The company’s strategy is clear: a complete transformation into a pure-play AI and software provider for the healthcare sector. This refocus involves divesting non-core assets. In the fourth quarter of 2025, strategic sales generated roughly 9.7 million CAD. More recently, in late March, Healwell signed a letter of intent to sell its subsidiary HEAL Access Canada to AI Maverick Intel. The deal would see Healwell receive 20 million exchangeable shares of the buyer and a secured vendor loan of approximately 5 million US dollars, contingent on AI Maverick Intel demonstrating a positive net working capital of at least 5 million USD at closing. A definitive agreement is targeted by May 29, 2026.
Should investors sell immediately? Or is it worth buying Healwell AI?
Looking ahead, management has set ambitious medium-term targets, aiming for roughly 50 percent growth in AI-related revenue and an adjusted EBITDA margin of about 10 percent for 2026. A key catalyst expected to drive this growth is the planned North American launch of the consolidated Amadeus AI platform in the first half of 2026. This platform unifies the company’s earlier products, Khure and Pentavere, under a single AI engine powered by its DARWEN technology. An international expansion is slated for late 2026.
Commercial momentum is building on other fronts as well. Healwell recently secured a multi-year, multi-million dollar contract in the US Health Information Exchange segment and now manages health data exchange networks across eleven countries. The scientific foundation for its technology continues to strengthen, with the 47th peer-reviewed publication on the DARWEN platform appearing in the Journal of Crohn’s and Colitis and being presented at the ECCO conference in mid-March. The company also holds strategic investments, including a stake in xAI, which is now part of the SpaceX ecosystem.
All eyes are now on the upcoming quarterly report. While a specific date for the Q1 2026 earnings has not been formally announced, the release is anticipated. The report must answer a pivotal question: can Healwell maintain its streak of positive adjusted EBITDA despite a seasonally softer quarter, while also demonstrating tangible commercial progress with its Amadeus AI rollout? Success on both fronts would strongly support the argument that its record-breaking 2025 performance was the start of a new trajectory, not an isolated peak.
Ad
Healwell AI Stock: Buy or Sell?! New Healwell AI Analysis from April 12 delivers the answer:
The latest Healwell AI figures speak for themselves: Urgent action needed for Healwell AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 12.
Healwell AI: Buy or sell? Read more here...
